Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)
McGill University Health Centre/Research Institute of the McGill University Health Centre
McGill University Health Centre/Research Institute of the McGill University Health Centre
Aurigene Discovery Technologies Limited
ImmunityBio, Inc.
Tango Therapeutics, Inc.
Instil Bio
Kaiser Permanente
Cancer Trials Ireland
M.D. Anderson Cancer Center
Deciphera Pharmaceuticals, LLC
Gustave Roussy, Cancer Campus, Grand Paris
Conjupro Biotherapeutics, Inc.
Roswell Park Cancer Institute
Taiho Oncology, Inc.
Therapex Co., Ltd
Sotio Biotech Inc.
Imugene Limited
The Methodist Hospital Research Institute
Gustave Roussy, Cancer Campus, Grand Paris
Pfizer
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
Centre Oscar Lambret
University of Iowa
Xencor, Inc.
Hoffmann-La Roche
Akeso
Hoffmann-La Roche
Deciphera Pharmaceuticals, LLC
Institut Bergonié
M.D. Anderson Cancer Center
Thomas Jefferson University
Novartis
Genmab
Pfizer
M.D. Anderson Cancer Center
Thomas Jefferson University
Pfizer
Mirati Therapeutics Inc.
VA Office of Research and Development
Novartis
Thomas Jefferson University
University of Michigan Rogel Cancer Center
MacroGenics
Mayo Clinic
Rutgers, The State University of New Jersey
Royal Marsden NHS Foundation Trust
Sun Yat-sen University
Roswell Park Cancer Institute